An antiprogestogen, also referred to as a progesterone receptor antagonist, is a class of pharmacological agents that bind to progesterone receptors and inhibit the biological actions of the endogenous hormone progesterone. By blocking progesterone signaling, antiprogestogens interfere with processes that depend on progesterone, such as the preparation of the endometrium for implantation, maintenance of early pregnancy, and certain aspects of menstrual cycle regulation.
Mechanism of Action
Antiprogestogens act primarily as competitive antagonists at the nuclear progesterone receptor (PR). Upon binding, they prevent progesterone from activating the receptor, thereby suppressing transcription of progesterone‑responsive genes. Some agents also exhibit partial agonist activity or possess mixed steroid receptor activity, influencing glucocorticoid or androgen pathways at higher concentrations.
Clinical Applications
| Indication | Representative Agents | Comments |
|---|---|---|
| Medical termination of early pregnancy | Mifepristone (RU‑486) | Used in combination with a prostaglandin analogue to induce uterine contraction and expel the conceptus. |
| Emergency contraception | Ulipristal acetate (Ella®) | Administered within 120 hours of unprotected intercourse; inhibits or delays ovulation and may affect endometrial receptivity. |
| Management of uterine fibroids (leiomyoma) | Ulipristal acetate (approved in some jurisdictions) | Reduces fibroid size and controls bleeding by antagonizing progesterone‑driven proliferation. |
| Endometriosis | Mifepristone (investigational) | Potential to limit ectopic endometrial tissue growth; usage remains investigational. |
| Cushing’s syndrome | Mifepristone (Korlym®) | At higher doses, antagonizes glucocorticoid receptors, providing metabolic benefits in hypercortisolism; the antiprogestogenic effect is a secondary property. |
Major Antiprogestogenic Compounds
- Mifepristone – A synthetic steroid with high affinity for progesterone receptors and moderate glucocorticoid receptor antagonism. First approved for medical abortion in the United States (2000) and subsequently for Cushing’s syndrome (2012).
- Ulipristal acetate – A selective progesterone receptor modulator (SPRM) demonstrating antagonistic activity at the PR with limited partial agonist effects. Licensed for emergency contraception (approved 2010) and, in certain regions, for the treatment of symptomatic uterine fibroids.
- Telapristone acetate – An experimental SPRM investigated for breast cancer prevention and endometriosis; development has been discontinued in several indications due to safety concerns.
- Onapristone – A non‑steroidal PR antagonist studied primarily for prostate and breast cancer; clinical development has been limited.
Pharmacokinetics
- Absorption: Oral bioavailability varies among agents; mifepristone is well‑absorbed (≈ 80 %); ulipristal acetate exhibits ≈ 60 % bioavailability.
- Distribution: Both agents are highly protein‑bound (> 90 %) and cross the placenta.
- Metabolism: Predominantly hepatic via CYP3A4; metabolites are generally less active.
- Elimination: Renal and fecal excretion; half‑life ranges from 18–30 hours (mifepristone) to 32–36 hours (ulipristal).
Adverse Effects
Commonly reported adverse events include:
- Nausea, vomiting, and abdominal pain
- Headache and dizziness
- Menstrual irregularities (e.g., prolonged bleeding)
- Fatigue and mood changes
Rare but serious effects have been associated with prolonged use, such as endometrial thickening, hyperplasia, or, in the case of high‑dose glucocorticoid antagonism, adrenal insufficiency.
Regulatory Status
Antiprogestogens are classified variously as prescription drugs, over‑the‑counter (emergency contraception in some countries), or investigational agents. Regulatory approvals differ by jurisdiction and by specific indication (e.g., mifepristone for abortion vs. Cushing’s syndrome).
Research Directions
Current research explores:
- Long‑term safety of SPRMs for chronic conditions (fibroids, endometriosis).
- Development of highly selective PR antagonists with minimal off‑target glucocorticoid activity.
- Potential applications in hormone‑responsive cancers, leveraging PR blockade to modulate tumor growth.
See Also
- Progesterone receptor
- Selective progesterone receptor modulators (SPRMs)
- Hormonal contraception
- Medical abortion
This entry reflects established information up to the 2024 knowledge cutoff and does not include speculative or unverified data.